- Home
- AENT vs PBYI Comparison
AENT vs PBYI Comparison
Compare AENT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- PBYI
- Stock Information
- Founded
- AENT 1990
- PBYI 2010
- Country
- AENT United States
- PBYI United States
- Employees
- AENT N/A
- PBYI N/A
- Industry
- AENT Durable Goods
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- PBYI Health Care
- Exchange
- AENT Nasdaq
- PBYI Nasdaq
- Market Cap
- AENT 161.5M
- PBYI 164.3M
- IPO Year
- AENT N/A
- PBYI N/A
- Fundamental
- Price
- AENT $5.56
- PBYI $3.56
- Analyst Decision
- AENT Strong Buy
- PBYI Strong Buy
- Analyst Count
- AENT 1
- PBYI 1
- Target Price
- AENT $10.00
- PBYI $7.00
- AVG Volume (30 Days)
- AENT 46.7K
- PBYI 302.0K
- Earning Date
- AENT 05-15-2025
- PBYI 07-31-2025
- Dividend Yield
- AENT N/A
- PBYI N/A
- EPS Growth
- AENT N/A
- PBYI 143.51
- EPS
- AENT 0.23
- PBYI 0.77
- Revenue
- AENT $1,072,641,000.00
- PBYI $232,709,000.00
- Revenue This Year
- AENT $4.77
- PBYI N/A
- Revenue Next Year
- AENT N/A
- PBYI N/A
- P/E Ratio
- AENT $25.32
- PBYI $4.64
- Revenue Growth
- AENT N/A
- PBYI 2.68
- 52 Week Low
- AENT $1.10
- PBYI $2.23
- 52 Week High
- AENT $11.57
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- AENT 77.47
- PBYI 56.71
- Support Level
- AENT $5.17
- PBYI $3.49
- Resistance Level
- AENT $6.37
- PBYI $3.65
- Average True Range (ATR)
- AENT 0.50
- PBYI 0.13
- MACD
- AENT 0.23
- PBYI 0.01
- Stochastic Oscillator
- AENT 75.89
- PBYI 75.80
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.